Market Size of Global Erythropoietin Stimulating Agents Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 8.60 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Erythropoietin Stimulating Agents Market Analysis
The erythropoietin stimulating agents (ESAs) market was valued at approximately USD 8,223 million in 2020 and is expected to witness a revenue of USD 13,436 million in 2026, with a CAGR of 8.6% over the forecast period.
According to a research study published in the American Journal of Kidney Disease, 2020, among the patients with COVID-19, with or without Acute Kidney Injury(AKI) and anemia, ESAs should be avoided in the therapy, as these patients are unlikely to mount an effective response to ESAs due to the inflammation. Thus, the risks associated with ESA treatments are expected to outweigh the potential benefits. Hence, the COVID-19 pandemic is expected to severely impact the studied market growth during the pandemic.
The ESAs market is driven by an increasing number of patients suffering from anemia, increasing applications in HIV infections and end-stage renal disorder, risks of thrombosis during surgeries, and pure red cell aplasia.
Anemia has been one of the serious nutrition-related diseases over the past few decades and is the major reason for increased morbidity and mortality, especially in low and middle-income countries. According to a research article published in PLoS One, 2019, Anemia is estimated to affect nearly 1.62 billion people worldwide and the prevalence of anemia was found to be 41.1% in Ethiopia. Additionally, as per the Lancet Global Health, 2019, India is estimated to account for nearly one-quarter of the global anemia cases. Iron Deficiency Anemia is common in children and women and is associated with sensory, motor, cognitive, language, and socioemotional deficits. Hence, the early detection and initiation of effective treatment strategies in the early stages of anemia are very important, especially among infants.
Other causes of anemia include parasite infections, such as ascaris, schistosomiasis, and hookworms, which can lower the hemoglobin (Hb) concentration in blood, along with heavy blood loss during menstruation among women.
Additionally, as per the Centers for Disease Control and Prevention's (CDC) 2019 report, it was estimated that about 37 million (15%) of the adult population in the United States had chronic kidney disease (CKD), which increases the severity of anemia. Therefore, as the number of people affected by anemia increases, the demand for erythropoietin stimulating agents (which aid in stimulating the production of more red blood cells) also increases. Hence, the aforementioned factors are expected to boost market growth over the forecast period. However, stringent regulatory guidelines to obtain product approvals and the adverse side effects of ESAs are expected to hamper the market growth.
Erythropoietin Stimulating Agents Industry Segmentation
As per the scope of the report, ESAs are similar to erythropoietin, as they stimulate the growth of red blood cells. ESAs have been approved for the treatment of anemia due to chronic kidney failure, chemotherapy, and HIV, and for the treatment of reduced red blood cells during critical surgical procedures. The erythropoietin stimulating agents market is segmented by type, application, and geography. By type, the market is segmented into epoetin alfa, epoetin beta, darbepoetin alfa, and other types. By application, the market is segmented into cancer, renal disorders, anti-retroviral treatment, neural diseases, and other applications. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report offers the value (in USD million) for the above segments.
| By Type | |
| Epoetin Alfa | |
| Epoetin Beta | |
| Darbepoetin Alfa | |
| Other Types |
| By Application | |
| Cancer | |
| Renal Disorders | |
| Anti-retroviral Treatment | |
| Neural Diseases | |
| Other Applications |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Erythropoietin Stimulating Agents Market Size Summary
The erythropoietin stimulating agents (ESAs) market is poised for significant growth, driven by the increasing prevalence of anemia and its applications in treating conditions such as HIV infections and end-stage renal disorder. Anemia, a major health concern, particularly in low and middle-income countries, is linked to various factors including nutritional deficiencies, parasitic infections, and chronic diseases like chronic kidney disease (CKD). The demand for ESAs, which stimulate red blood cell production, is expected to rise as the number of anemia cases increases. However, the market faces challenges from stringent regulatory guidelines and potential adverse side effects of ESA treatments. The COVID-19 pandemic has also impacted market growth, as the risks associated with ESA treatments in COVID-19 patients with anemia have led to a cautious approach in their use.
In the cancer segment, ESAs are crucial for improving the quality of life and clinical outcomes for patients undergoing chemotherapy, as they address anemia caused by myelosuppression and erythropoietin deficiency. The market is further bolstered by the high incidence of cancer and the need for effective anemia management in these patients. North America is expected to hold the largest market share due to the high prevalence of disorders leading to anemia and the significant number of cancer cases. The competitive landscape of the ESAs market includes major players like Amgen, Thermo Fisher Scientific, and Pfizer Inc., who are actively involved in developing and expanding ESA products. Despite the challenges posed by the pandemic, the market is anticipated to grow as pharmaceutical companies continue to innovate and address the needs of anemia patients globally.
Global Erythropoietin Stimulating Agents Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Disease Burden of Anemia
-
1.2.2 Rising Applications in HIV Infections and End-stage Renal Disorder
-
1.2.3 Risks of Thrombosis, during Surgeries, and Pure Red Cell Aplasia
-
-
1.3 Market Restraints
-
1.3.1 Stringent Regulatory Guidelines
-
1.3.2 Adverse Side Effects
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Type
-
2.1.1 Epoetin Alfa
-
2.1.2 Epoetin Beta
-
2.1.3 Darbepoetin Alfa
-
2.1.4 Other Types
-
-
2.2 By Application
-
2.2.1 Cancer
-
2.2.2 Renal Disorders
-
2.2.3 Anti-retroviral Treatment
-
2.2.4 Neural Diseases
-
2.2.5 Other Applications
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States (By Type and By Application)
-
2.3.1.2 Canada (By Type and By Application)
-
2.3.1.3 Mexico (By Type and By Application)
-
-
2.3.2 Europe
-
2.3.2.1 Germany (By Type and By Application)
-
2.3.2.2 United Kingdom (By Type and By Application)
-
2.3.2.3 France (By Type and By Application)
-
2.3.2.4 Italy (By Type and By Application)
-
2.3.2.5 Spain (By Type and By Application)
-
2.3.2.6 Rest of Europe (By Type and By Application)
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China (By Type and By Application)
-
2.3.3.2 Japan (By Type and By Application)
-
2.3.3.3 India (By Type and By Application)
-
2.3.3.4 Australia (By Type and By Application)
-
2.3.3.5 South Korea (By Type and By Application)
-
2.3.3.6 Rest of Asia-Pacific (By Type and By Application)
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC (By Type and By Application)
-
2.3.4.2 South Africa (By Type and By Application)
-
2.3.4.3 Rest of Middle East and Africa (By Type and By Application)
-
-
2.3.5 South America
-
2.3.5.1 Brazil (By Type and By Application)
-
2.3.5.2 Argentina (By Type and By Application)
-
2.3.5.3 Rest of South America (By Type and By Application)
-
-
-
Global Erythropoietin Stimulating Agents Market Size FAQs
What is the current Global Erythropoietin Stimulating Agents Market size?
The Global Erythropoietin Stimulating Agents Market is projected to register a CAGR of 8.60% during the forecast period (2024-2029)
Who are the key players in Global Erythropoietin Stimulating Agents Market?
Amgen Inc., F. Hoffmann La Roche Ltd, Thermo Fisher Scientific, Johnson and Johnson and Pfizer Inc. are the major companies operating in the Global Erythropoietin Stimulating Agents Market.
